US Patent

US11708370 — Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Composition of Matter · Assigned to Principia Biopharma Inc · Expires 2041-02-20 · 15y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects solid forms of a specific chemical compound and methods for making and using it to treat disorders and conditions mediated by BTK activity.

USPTO Abstract

Solid forms of Compound (I):are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US11708370
Jurisdiction
US
Classification
Composition of Matter
Expires
2041-02-20
Drug substance claim
Yes
Drug product claim
No
Assignee
Principia Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.